Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

460 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Effects of atorvastatin on renal function in patients with dyslipidemia and chronic kidney disease: rationale and design of the ASsessment of clinical Usefulness in CKD patients with Atorvastatin (ASUCA) trial.
Ueshima K, Kasahara M, Koya D, Babazono T, Sato T, Imamoto M, Yasuno S, Fujimoto A, Tanaka S, Kimura G, Nakao K. Ueshima K, et al. Clin Exp Nephrol. 2013 Apr;17(2):211-7. doi: 10.1007/s10157-012-0676-5. Epub 2012 Sep 6. Clin Exp Nephrol. 2013. PMID: 22948416 Clinical Trial.
Reciprocal expression of MRTF-A and myocardin is crucial for pathological vascular remodelling in mice.
Minami T, Kuwahara K, Nakagawa Y, Takaoka M, Kinoshita H, Nakao K, Kuwabara Y, Yamada Y, Yamada C, Shibata J, Usami S, Yasuno S, Nishikimi T, Ueshima K, Sata M, Nakano H, Seno T, Kawahito Y, Sobue K, Kimura A, Nagai R, Nakao K. Minami T, et al. Among authors: ueshima k. EMBO J. 2012 Nov 28;31(23):4428-40. doi: 10.1038/emboj.2012.296. Epub 2012 Oct 26. EMBO J. 2012. PMID: 23103763 Free PMC article.
Effects of atorvastatin on renal function in patients with dyslipidemia and chronic kidney disease: assessment of clinical usefulness in CKD patients with atorvastatin (ASUCA) trial.
Kimura G, Kasahara M, Ueshima K, Tanaka S, Yasuno S, Fujimoto A, Sato T, Imamoto M, Kosugi S, Nakao K. Kimura G, et al. Among authors: ueshima k. Clin Exp Nephrol. 2017 Jun;21(3):417-424. doi: 10.1007/s10157-016-1304-6. Epub 2016 Jul 8. Clin Exp Nephrol. 2017. PMID: 27392909 Free PMC article. Clinical Trial.
Effectiveness of nationwide screening and lifestyle intervention for abdominal obesity and cardiometabolic risks in Japan: The metabolic syndrome and comprehensive lifestyle intervention study on nationwide database in Japan (MetS ACTION-J study).
Nakao YM, Miyamoto Y, Ueshima K, Nakao K, Nakai M, Nishimura K, Yasuno S, Hosoda K, Ogawa Y, Itoh H, Ogawa H, Kangawa K, Nakao K. Nakao YM, et al. Among authors: ueshima k. PLoS One. 2018 Jan 9;13(1):e0190862. doi: 10.1371/journal.pone.0190862. eCollection 2018. PLoS One. 2018. PMID: 29315322 Free PMC article.
Intensive Treat-to-Target Statin Therapy in High-Risk Japanese Patients With Hypercholesterolemia and Diabetic Retinopathy: Report of a Randomized Study.
Itoh H, Komuro I, Takeuchi M, Akasaka T, Daida H, Egashira Y, Fujita H, Higaki J, Hirata KI, Ishibashi S, Isshiki T, Ito S, Kashiwagi A, Kato S, Kitagawa K, Kitakaze M, Kitazono T, Kurabayashi M, Miyauchi K, Murakami T, Murohara T, Node K, Ogawa S, Saito Y, Seino Y, Shigeeda T, Shindo S, Sugawara M, Sugiyama S, Terauchi Y, Tsutsui H, Ueshima K, Utsunomiya K, Yamagishi M, Yamazaki T, Yo S, Yokote K, Yoshida K, Yoshimura M, Yoshimura N, Nakao K, Nagai R; EMPATHY Investigators. Itoh H, et al. Among authors: ueshima k. Diabetes Care. 2018 Jun;41(6):1275-1284. doi: 10.2337/dc17-2224. Epub 2018 Apr 6. Diabetes Care. 2018. PMID: 29626074 Clinical Trial.
Achieving LDL cholesterol target levels <1.81 mmol/L may provide extra cardiovascular protection in patients at high risk: Exploratory analysis of the Standard Versus Intensive Statin Therapy for Patients with Hypercholesterolaemia and Diabetic Retinopathy study.
Itoh H, Komuro I, Takeuchi M, Akasaka T, Daida H, Egashira Y, Fujita H, Higaki J, Hirata KI, Ishibashi S, Isshiki T, Ito S, Kashiwagi A, Kato S, Kitagawa K, Kitakaze M, Kitazono T, Kurabayashi M, Miyauchi K, Murakami T, Murohara T, Node K, Ogawa S, Saito Y, Seino Y, Shigeeda T, Shindo S, Sugawara M, Sugiyama S, Terauchi Y, Tsutsui H, Ueshima K, Utsunomiya K, Yamagishi M, Yamazaki T, Yo S, Yokote K, Yoshida K, Yoshimura M, Yoshimura N, Nakao K, Nagai R; EMPATHY Investigators. Itoh H, et al. Among authors: ueshima k. Diabetes Obes Metab. 2019 Apr;21(4):791-800. doi: 10.1111/dom.13575. Epub 2018 Dec 6. Diabetes Obes Metab. 2019. PMID: 30393955 Free PMC article. Clinical Trial.
Rationale and design of the EMPYREAN study.
Motoki H, Masuda I, Yasuno S, Oba K, Shoin W, Usami S, Saito Y, Waki M, Komatsu M, Ueshima K, Nakagawa Y, Son C, Yonemitsu S, Hiramitsu S, Konda M, Onishi K, Kuwahara K. Motoki H, et al. Among authors: ueshima k. ESC Heart Fail. 2020 Oct;7(5):3134-3141. doi: 10.1002/ehf2.12825. Epub 2020 Jun 23. ESC Heart Fail. 2020. PMID: 32578353 Free PMC article. Clinical Trial.
Long-term effects of candesartan and amlodipine on cardiovascular mortality and morbidity in Japanese high-risk hypertensive patients: rationale, design, and characteristics of candesartan antihypertensive survival evaluation in Japan extension (CASE-J Ex).
Ueshima K, Oba K, Yasuno S, Fujimoto A, Sato T, Fukiyama K, Azuma J, Ogihara T, Saruta T, Nakao K; Candesartan Antihypertensive Survival Evaluation in Japan Trial Group. Ueshima K, et al. Contemp Clin Trials. 2009 Jan;30(1):97-101. doi: 10.1016/j.cct.2008.09.006. Epub 2008 Sep 13. Contemp Clin Trials. 2009. PMID: 18824134
460 results